<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796128</url>
  </required_header>
  <id_info>
    <org_study_id>NIPAL02</org_study_id>
    <nct_id>NCT05796128</nct_id>
  </id_info>
  <brief_title>NIPPV vs.nCPAP During LISA Procedure</brief_title>
  <acronym>NIPAL</acronym>
  <official_title>Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Airway Pressure Durante la Somministrazione Del Surfattante Con Tecnica LISA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this randomized controlled study is to compare the efficacy of using NIPPV versus&#xD;
      NCPAP during the LISA procedure in very preterm infants.&#xD;
&#xD;
      The main question it aims to answer is:&#xD;
&#xD;
      â€¢ Does NIPPV during the LISA procedure decrease the need for a second dose of surfactant or&#xD;
      the need of mechanical ventilation during the first 72 hours of life in comparison with&#xD;
      NCPAP? Infants with gestational age between 25+0 and 31+6 weeks of gestation with RDS who do&#xD;
      not require VM and treated with NCPAP and FiO2 &gt;0.30 within the first 6 hours of life who&#xD;
      received the first dose of caffeine will be eligible for enrollment in the study Participants&#xD;
      will be randomized to receive surfactant with conventional LISA procedure, i.e. performed&#xD;
      during NCPAP, or with LISA procedure performed during NIPPV.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">January 23, 2023</completion_date>
  <primary_completion_date type="Actual">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surfactant or mechanical ventilation</measure>
    <time_frame>The need for a second dose of surfactant or mechanical ventilation will be evaluated within the first 72 hour of life</time_frame>
    <description>Need for a second dose of surfactant or mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Noninvasive ventilation</measure>
    <time_frame>Participants will be monitored for the duration of their hospital stay, which is an average of 10 weeks</time_frame>
    <description>Duration of noninvasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>Participants will be monitored for the duration of their hospital stay, which is an average of 10 weeks</time_frame>
    <description>Duration ofmechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia</measure>
    <time_frame>Participants will be monitored for the duration of their hospital stay, which is an average of 10 weeks</time_frame>
    <description>Frequency of mild, moderate, and severe bronchopulmonary dysplasia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>LISA with NCPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, infants will receive NCPAP during LISA procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LISA with NIPPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, infants will receive NIPPV during LISA procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nasal Intermittent Positive Pressure Ventilation (NIPPV)</intervention_name>
    <description>In this group, infants will receive NIPPV during LISA procedure.</description>
    <arm_group_label>LISA with NIPPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nasal continuous positive airway pressure (NCPAP)</intervention_name>
    <description>In this group, infants will receive NCPAP during LISA procedure.</description>
    <arm_group_label>LISA with NCPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  -Infants with gestational age between 25+0 and 31+6 gestational weeks,&#xD;
&#xD;
          -  -RDS which does not require MV&#xD;
&#xD;
          -  -Treatment with NCPAP and FiO2 &gt;0.30 within the first 6 hours of life,&#xD;
&#xD;
          -  -First dose of caffeine administered&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  -absence of informed consent,&#xD;
&#xD;
          -  -major congenital malformations,&#xD;
&#xD;
          -  -hydrops fetalis,&#xD;
&#xD;
          -  -chromosomal diseases,&#xD;
&#xD;
          -  -previous treatment with surfactant,&#xD;
&#xD;
          -  -cardiorespiratory instability requiring treatment with vasoactive drugs,&#xD;
&#xD;
          -  -pneumothorax,&#xD;
&#xD;
          -  -death within 72 hours of life.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Hours</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Careggi University Hospital, Division of Neonatology</name>
      <address>
        <city>Florence</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Carlo Dani</investigator_full_name>
    <investigator_title>Full Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Surfactant</keyword>
  <keyword>LISA procedure</keyword>
  <keyword>Preterm infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

